Cargando…
Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280620/ https://www.ncbi.nlm.nih.gov/pubmed/35846273 http://dx.doi.org/10.3389/fendo.2022.892127 |
_version_ | 1784746688103055360 |
---|---|
author | Min, Qiuxia Wang, Yan Jin, TaiCheng Zhu, Lei Wu, XianYan Li, YiKun Wang, YanJiao Xu, Ning |
author_facet | Min, Qiuxia Wang, Yan Jin, TaiCheng Zhu, Lei Wu, XianYan Li, YiKun Wang, YanJiao Xu, Ning |
author_sort | Min, Qiuxia |
collection | PubMed |
description | Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, the regulatory role of probiotics on intestinal metabolites after treatment of type 2 diabetes mellitus remains unclear. The purpose of this study was to investigate the therapeutic effect of probiotics on type 2 diabetes mellitus and its regulatory effect on short-chain fatty acids, which are metabolites of intestinal microorganisms. I collected feces from 15 patients with diabetes before treatment and 15 patients with type 2 diabetes after treatment with GLP-1 and probiotics. The abundance of short-chain fatty acids in feces was determined by GC-MS. Results Both GLP-1 and probiotics could improve the levels of blood glucose, urine glucose and BMI in patients with type 2 diabetes. After glP-1 treatment, two short-chain fatty acids (butyric acid and valerate acid) in intestine were significantly changed. Propionic acid and isovalerate were significantly changed after probiotic treatment. At the same time, KEGG signal pathway enrichment results showed that probiotics intervention mainly achieved the purpose of treating type 2 diabetes through regulating protein and carbohydrate metabolism. Taken together, our study shows changes in intestinal short-chain fatty acids after probiotics or GLP-1 treatment of type 2 diabetes, which will provide us with new insights into the mechanism of probiotics treatment of type 2 diabetes, as well as potential intervention targets for diabetes treatment. |
format | Online Article Text |
id | pubmed-9280620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92806202022-07-15 Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus Min, Qiuxia Wang, Yan Jin, TaiCheng Zhu, Lei Wu, XianYan Li, YiKun Wang, YanJiao Xu, Ning Front Endocrinol (Lausanne) Endocrinology Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people’s lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, the regulatory role of probiotics on intestinal metabolites after treatment of type 2 diabetes mellitus remains unclear. The purpose of this study was to investigate the therapeutic effect of probiotics on type 2 diabetes mellitus and its regulatory effect on short-chain fatty acids, which are metabolites of intestinal microorganisms. I collected feces from 15 patients with diabetes before treatment and 15 patients with type 2 diabetes after treatment with GLP-1 and probiotics. The abundance of short-chain fatty acids in feces was determined by GC-MS. Results Both GLP-1 and probiotics could improve the levels of blood glucose, urine glucose and BMI in patients with type 2 diabetes. After glP-1 treatment, two short-chain fatty acids (butyric acid and valerate acid) in intestine were significantly changed. Propionic acid and isovalerate were significantly changed after probiotic treatment. At the same time, KEGG signal pathway enrichment results showed that probiotics intervention mainly achieved the purpose of treating type 2 diabetes through regulating protein and carbohydrate metabolism. Taken together, our study shows changes in intestinal short-chain fatty acids after probiotics or GLP-1 treatment of type 2 diabetes, which will provide us with new insights into the mechanism of probiotics treatment of type 2 diabetes, as well as potential intervention targets for diabetes treatment. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9280620/ /pubmed/35846273 http://dx.doi.org/10.3389/fendo.2022.892127 Text en Copyright © 2022 Min, Wang, Jin, Zhu, Wu, Li, Wang and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Min, Qiuxia Wang, Yan Jin, TaiCheng Zhu, Lei Wu, XianYan Li, YiKun Wang, YanJiao Xu, Ning Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title | Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title_full | Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title_fullStr | Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title_full_unstemmed | Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title_short | Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus |
title_sort | analysis of intestinal short-chain fatty acid metabolism profile after probiotics and glp-1 treatment for type 2 diabetes mellitus |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280620/ https://www.ncbi.nlm.nih.gov/pubmed/35846273 http://dx.doi.org/10.3389/fendo.2022.892127 |
work_keys_str_mv | AT minqiuxia analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT wangyan analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT jintaicheng analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT zhulei analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT wuxianyan analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT liyikun analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT wangyanjiao analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus AT xuning analysisofintestinalshortchainfattyacidmetabolismprofileafterprobioticsandglp1treatmentfortype2diabetesmellitus |